



February 12, 2026

Company name: ROHTO Pharmaceutical Co., Ltd.

Representative: Hidetoshi Segi,

President and Representative Director

(Code: 4527 TSE Prime)

Contact: Masaya Saito, Vice President and CFO

(TEL: 06-6758-8223)

Notice of Revision of Earnings Forecast
and Revision of Dividend Forecast (Dividend Increase)

ROHTO PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that, in light of the recent trends in business performance, the Company has revised its consolidated earnings forecast announced on November 13, 2025, and the Company has revised the year-end dividend announced on November 13, 2025, as described below.

The forecast indicated below is also disclosed in the “Consolidated Financial Results for the Nine Months Ended December 31, 2025 [Japanese GAAP].”

1. Revisions to the earnings forecast

(1) Details of the revisions

Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A) (Announced on November 13, 2025)	338,500	39,500	44,000	32,000	141.62
Revised forecast (B)	340,500	40,500	46,500	33,000	146.04
Change (B-A)	2,000	1,000	2,500	1,000	
Percentage change (%)	0.6	2.5	5.7	3.1	
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2025)	308,625	38,234	39,725	30,841	135.38

(2) Reasons for the revisions

The Company has revised the consolidated financial earnings forecast announced on November 13, as the performance in Asia, and Americas during the Third Quarter of the Fiscal Year exceeded expectations, and the Fourth Quarter is also expected to remain strong. Net sales, operating income, ordinary income, and profit attributable to owners of parent are all expected to exceed the previous forecast, resulting in higher sales and profit. The expected exchange rates have been revised to 150 yen per U.S. dollar and 20.82 yen per Chinese yuan.

Rohto Pharmaceutical Co., Ltd.

*Previous period results are calculated based on figures after retrospective adjustments, reflecting the finalization of the provisional accounting treatment for the business combination conducted in the first quarter of the fiscal year ending March 31, 2026.

2. Revision of Year-end Dividend Forecast.

(1) Details of the revisions

Revision of dividend forecast for the fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

	Dividend per share		
	2nd quarter-end	Year-end	Total
Previous forecast (Announced on November 13, 2025)	21.00	22.00	43.00
Revised forecast		23.00	44.00
Current period results	21.00		
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2025)	16.00	20.00	36.00

The Company executed a 2-for-1 stock split of shares of common stock on January 1, 2023.

(2) Reasons for the revisions

Consistently and continually returning to shareholders the profits earned through business activities is one of our highest priorities. The fundamental policy is to pay a dividend based on results of operations. Based on the earnings forecast for the fiscal year ending March 31, 2026 (April 1, 2025 to March 31, 2026), to enhance the return of profits to shareholders, for said fiscal year, the Company has decided to increase the year-end dividend by 1 yen to 23 yen per share. As such, the total annual dividend will be 44 yen per share.

*The above forecasts are based on information available as of the date of announcement. Actual results may differ from the forecasts due to various factors.